BERBERİN HCL İÇEREN SICAKLIĞA DUYARLI İN SİTU JELLEŞEN OFTALMİK İLAÇ TAŞIYICI SİSTEMİN TASARIMI VE DEĞERLENDİRİLMESİ

Öz

Amaç: Bu çalışmada, oftalmik ilaç taşıyıcı sistemler için farklı fizyolojik uyaranlara duyarlı polimerlerin birleştirilmesiyle geliştirilen in situ jelleşen bir formülasyonun etkinliği araştırılmıştır. Etkin madde olarak berberin hidroklorür seçilmiştir. Çalışmanın temel amacı, uygulama kolaylığı sunan, oküler yüzeyde kalıcılığı artırarak terapötik etkinliği iyileştiren ve doz tekrarını azaltarak hasta uyumunu artıran yenilikçi bir oftalmik ilaç taşıyıcı sistem tasarlamaktı. Gereç ve Yöntem: Formülasyon, Pluronic F127, kitozan ve κ-karragenan polimerleri kullanılarak hazırlanmıştır. Pluronic F127 ve kitozan çözeltileri soğuk yöntemle, κ-karragenan çözeltisi ise 50°C’de hazırlanmıştır. Geliştirilen sistem berraklık, pH ve jelleşme sıcaklığı açısından değerlendirilmiştir. Elde edilen sonuçlara dayanarak, literatür verilerine uygun şekilde, optimal özellikler gösteren formülasyona 0.26 mg/ml konsantrasyonunda Berberin HCl eklenmiştir. Etken madde salım profili, 35°C’de pH 7.4 izotonik fosfat tamponu içinde diyaliz membran yöntemiyle değerlendirilmiştir. Stabilite çalışmaları kapsamında formülasyonlar 25 ± 2°C / %60 ± 5 bağıl nemde ve 5 ± 3°C’de bir ay boyunca saklanmıştır. Saklama süresi sonunda tüm analizler tekrarlanmış ve etken madde salım profilleri fark (f₁) ve benzerlik (f₂) faktörleri kullanılarak karşılaştırılmıştır. Sonuç ve Tartışma: Bu çalışmada, Berberin HCl içeren, üçlü polimer sistemiyle formüle edilmiş in situ jelleşen bir oftalmik ilaç taşıyıcı sistem geliştirilmiştir. Elde edilen bulgular, hasta uyumunu artırabilecek bu sistemin konvansiyonel göz damlalarına potansiyel bir alternatif olabileceğini göstermektedir; ancak bu durumun in vivo çalışmalarla desteklenmesi gerekmektedir.

Anahtar Kelimeler

• Berberin HCl
• in situ jelleşme
• oftalmik formülasyon
• oftalmik ilaç taşıyıcı sistem
• polimer bazlı

Proje Numarası

1919B012306007

DESIGN AND EVALUATION OF A TEMPERATURE RESPONSIVE IN SITU GELLING OPHTHALMIC DRUG DELIVERY SYSTEM CONTAINING BERBERINE HCL

Öz

Objective: In this study, the efficacy of an in situ gelling formulation developed by combining polymers sensitive to different physiological stimuli for ophthalmic drug delivery systems was investigated. As the active pharmaceutical ingredient, berberine hydrochloride was selected. The primary aim of the study was to design an innovative ophthalmic drug delivery system that offers ease of administration, improves therapeutic efficacy by increasing retention on the ocular surface, and enhances patient compliance by reducing the frequency of dosing. Material and Method: The formulation was prepared using Pluronic F127, chitosan, and κ-carrageenan polymers. Pluronic F127 and chitosan solutions were prepared by the cold method, while the κ-carrageenan solution was prepared at 50°C. The developed system was evaluated in terms of clarity, pH, and gelation temperature. Based on the results obtained, Berberine HCl was added at a concentration of 0.26 mg/ml, in accordance with literature data, to the formulation that exhibited optimal characteristics. The drug release profile was evaluated at 35°C in pH 7.4 isotonic phosphate buffer using the dialysis membrane method. For the stability studies, the formulations were stored for one month at 25 ± 2°C / 60 ± 5% relative humidity and 5 ± 3°C. At the end of the storage period, all analyses were repeated and the drug release profiles were compared using difference (f₁) and similarity (f₂) factors. Result and Discussion: In this study, an in situ gelling ophthalmic drug delivery system containing berberine HCl was developed using a triple polymer system. The results suggest that this system, which may enhance patient compliance, could be a potential alternative to conventional eye drops; however, this needs to be supported by in vivo studies.

Anahtar Kelimeler

• Berberine HCl
• in situ gelation
• ophthalmic drug delivery system
• ophthalmic formulation
• polymer based

Destekleyen Kurum

TÜBİTAK

Proje Numarası

1919B012306007

Teşekkür

Bu araştırma TÜBİTAK 2209A kapsamında desteklenmiştir. Teşekkür ederiz.

Kaynakça

1. 1. Karataş, A., Boluk, A., Algan, A.H. (2015). Poloxamer/chitosan in situ gelling system for ocular delivery of ofloxacin. Current Drug Therapy, 9(4), 219-225. [CrossRef]
2. 2. Gupta, H., Velpandian, T., Jain, S. (2010). Ion-and pH-activated novel in-situ gel system for sustained ocular drug delivery. Journal of Drug Targeting, 18(7), 499-505. [CrossRef]
3. 3. Polat, H.K., Ünal, S., Aytekin, E., Gözcü, S. (2022). Oküler ilaç taşıyıcı sistemler: Geleneksel derleme. Journal of Literature Pharmacy Sciences, 11(3), 189-200. [CrossRef]
4. 4. Qian, L., Cook, M.T., Dreiss, C.A. (2025). In situ gels for nasal delivery: Formulation, characterization and applications. Macromolecular Materials and Engineering, 310, 2400356. [CrossRef]
5. 5. Khairnar, M.R.G., Verma, M.G., Wani, M.R., Tasgaonkar, D.R.R. (2024). Comprehensive review on polymers used in in situ gelling system. International Journal for Research in Applied Science and Engineering Technology. [CrossRef]
6. 6. D’Souza, A., Pissurlenkar, R.R. (2024). Design and development of nanoparticle-loaded in-situ gel for enhanced and sustained ophthalmic delivery. Drug Delivery Letters, 15(2), 145-162. [CrossRef]
7. 7. Waghmode, R.R., Mali, D.P., Salve, P., Dhadde, S.B. (2024). A bird eye view on in-situ ophthalmic gel:challenges and opportunities. Drug Delivery Technology, 14(3), 1801-1810. [CrossRef]
8. 8. Rahman, M.A., Rabbani, M. (2020). Steady-state thermophysical simulation of a 3D CAD model of human-eye. 2020 IEEE Region 10 Symposium, 1339-1342. [CrossRef]

9. 9. Sudhir Dhote, N., Dineshbhai Patel, R., Kuwar, U., Agrawal, M., Alexander, A., Jain, P., Ajazuddin. (2024). Application of thermoresponsive smart polymers based in situ gel as a novel carrier for tumor targeting. Current Cancer Drug Targets, 24(4), 375-396. [CrossRef]
10. 10. Darge, H.F., Andrgie, A.T., Tsai, H.C., Lai, J.Y. (2019). Polysaccharide and polypeptide based injectable thermo-sensitive hydrogels for local biomedical applications. International Journal of Biological Macromolecules, 15(133), 545-563. [CrossRef]
11. 11. Paul, S., Majumdar, S., Chakraborty, M. (2023). Revolutionizing ocular drug delivery: Recent advancements in in situ gel technology. Bulletin of the National Research Centre, 47(1), 154. [CrossRef]
12. 12. Alsheikh, R., Haimhoffer, Á., Nemes, D., Ujhelyi, Z., Fehér, P., Józsa, L., Vasvári, G., Pető, Á., Kósa, D., Nagy, L. (2024). Formulation of thermo-sensitive in situ gels loaded with dual spectrum antibiotics of azithromycin and ofloxacin. Polymers, 16(21), 2954. [CrossRef]
13. 13. Ph, A.M., Satyananda, S. (2014). pH-induced in situ gelling system of an anti-infective drug for sustained ocular delivery. Journal of Applied Pharmaceutical Science, 4(1), 101-104. [CrossRef]
14. 14. Kurniawansyah, I.S., Rahmi, F., Sopyan, I. (2018). pH triggered in-situ gelling ophthalmic drug delivery system. International Journal of Drug Delivery Technology, 8(01), 1-5. [CrossRef]
15. 15. Castro, B.F.M., de Oliveira Fulgêncio, G., Domingos, L.C., Cotta, O.A.L., Silva-Cunha, A., Fialho, S.L. (2020). Positively charged polymeric nanoparticles improve ocular penetration of tacrolimus after topical administration. Journal of Drug Delivery Science and Technology, 60, 101912. [CrossRef]
16. 16. Vigani B., Rossi S., Gentile, M., Sandri., G., Bonferoni, M.C., Cavalloro, V., Martino, E., Collina, S., Ferrari, F. (2019). Development of a mucoadhesive and an in situ gelling formulation based on κ-carrageenan for application on oral mucosa and esophagus walls. ıı. loading of a bioactive hydroalcoholic extract. Marine Drugs, 17(3), 153. [CrossRef]
17. 17. Suchita, G., Juvatkar, PV., Simita, T., Suvarna, B. (2020). Ion-activated in situ gelling system of levofloxacin for sustained ophthalmic delivery. American Journal of Pharmtech Research, 10(6), 33-41. [CrossRef]
18. 18. Şimşek, C., Doğru, M., Kojima, T., Tsubota, K. (2018). Current management and treatment of dry eye disease. Turkish Journal of Pphthalmology, 48(6), 309. [CrossRef]
19. 19. Akocak, S. (2024). Sağlık & Bilim 2024: Eczacılık-I, Efe Akademi, İstanbul, p.137.
20. 20. Sahdev, A.K., Sethi, B., Singh, A., Sharma, N., Purwar, S. (2018). Conjunctivitis: Types, diagnosis and treatment under different therapies. Asian Journal of Pharmacy and Pharmacology, 4(4), 421-428. [CrossRef]
21. 21. Biswas, N., Gupta, S., Das, G., Kumar, N., Mongre, P., Haldar, D., Beri, S. (2001). Evaluation of Ophthacare® eye drops-a herbal formulation in the management of various ophthalmic disorders. Phytotherapy Research, 15(7), 618-620. [CrossRef]
22. 22. Bruijn, C., Christ, F., Dziabo, A., Vigh, J. (2003). Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives. 2005/ EP1492551A2.
23. 23. Güngör Ak, A. (2022). PhD Thesis. Berberı̇n fosfolı̇pı̇d kompleksı̇ yüklü kı̇tozan mı̇kropartı̇küllerı̇n hazırlanması ve i̇n vı̇tro/i̇n vı̇vo değerlendı̇rı̇lmesı̇. Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, Turkey.
24. 24. Han, Y., Guo, S., Li, Y., Li, J., Zhu, L., Liu, Y., Lv, Y., Yu, D., Zheng, L., Huang, C. (2023). Berberine ameliorate inflammation and apoptosis via modulating PI3K/AKT/NFκB and MAPK pathway on dry eye. Phytomedicine, 121, 155081. [CrossRef]
25. 25. Li, S., Gaur, U., Chong, C.M., Lin, S., Fang, J., Zeng, Z., Wang, H., Zheng, W. (2018). Berberine protects human retinal pigment epithelial cells from hydrogen peroxide-ınduced oxidative damage through activation of AMPK. International Journal of Molecular Sciences, 19(6), 1736. [CrossRef]
26. 26. Zhai, J., Li, Z., Zhang, H., Ma, L., Ma, Z., Zhang, Y., Zou, J., Li, M., Ma, L., Wang, X. (2020). Berberine protects against diabetic retinopathy by inhibiting cell apoptosis via deactivation of the NF-κB signaling pathway. Molecular Medicine Reports, 22(5), 4227-4235. [CrossRef]
27. 27. Diao, J., Chen, X., Mou, P., Ma, X., Wei, R. (2022). Potential therapeutic activity of berberine in thyroid-associated ophthalmopathy: Inhibitory effects on tissue remodeling in orbital fibroblasts. Investigative Ophthalmology and Visual Science, 63(10), 6-6. [CrossRef]
28. 28. Murine Web site. (2023). Retrieved June 10, 2025, from https://murine.com./ Accessed date: 14.03.2025.
29. 29. Asasutjarit, R., Thanasanchokpibull, S., Fuongfuchat, A., Veeranondha, S. (2011). Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels. International Journal of Pharmaceutics, 411(1-2), 128-135. [CrossRef]
30. 30. Gupta, P., Jain, S., Mathur, J., Mishra, P., Mishra, A.K., Velpandian, T. (2007). Sustained ocular drug delivery from a temperature and ph triggered novel in situ gel system. Drug Delivery, 14(8), 507-514. [CrossRef]
31. 31. Karataş, A., Sonakin, Ö., Kiliçarslan, M., Baykara, T. (2009). Poly (ε-caprolactone) microparticles containing Levobunolol HCl prepared by a multiple emulsion (W/O/W) solvent evaporation technique: Effects of some formulation parameters on microparticle characteristics. Journal of Microencapsulation, 26(1), 63-74. [CrossRef]
32. 32. Costa, P., Lobo, J.M.S. (2001). Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13(2), 123-133. [CrossRef]
33. 33. Bohorquez, M., Koch, C., Trygstad, T., Pandit, N. (1999). A Study of the temperature-dependent micellization of pluronic F127. Journal of Colloid and Interface Science, 216, 34-40. [CrossRef]
34. 34. Gratieri, T., Gelfuso, G.M. Rocha, E.M., Sarmento, M.G., Freitas, O., Lopez, R.F.V. (2010) Poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. European Journal of Pharmaceutics and Biopharmaceutics, 75, 186-193. [CrossRef]
35. 35. Sarada, K., Firoz, S., Padmini K. (2014). In-Situ Gelling System: A Review. International Journal of Current Pharmaceutical Review and Research, 15(5), 76-90.
36. 36. Forrester, J.V., Dick, A.D., McMenamin, P.G., Roberts, F., Pearlman, E. (2016). General and ocular pharmacology. The Eye, 338-369. [CrossRef]
37. 37. Jones, D. S. (2016). FASTtrack Pharmaceutics dosage form and design, 2nd Edition, Pharmaceutical press, London, p.167.
38. 38. Aulton, M.E., Taylor, K. (2013). Aulton's pharmaceutics: the design and manufacture of medicines, 4th Edition, Elsevier, London, p.710.
39. 39. Troy D.B. (2006). Remington: The science and practice of pharmacy, 21st Edition, Lippincott Williams & Wilkins, Philadelphia, p.850.